Clinical trial NCT02649751: Evaluation of (R)-Roscovitine Safety and Effects in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation
Official title: A Phase II, Dose Ranging, Multicenter, Double-blind, Placebo Controlled Study to Evaluate Safety and Effects of (R)-Roscovitine in Adults Subjects With Cystic Fibrosis, Carrying 2 Cystic Fibrosis Causing Mutations With at Least One F508del-CFTR Mutation and Chronically Infected With Pseudomonas Aeruginosa, a Study Involving 36 CF Patients (24 Treated, 12 Controls). ROSCO-CF.
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Cystic Fibrosis
Keywords: Cystic Fibrosis
Roscovitine
Seliciclib
CYC202
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
Collaborators: name: ManRos Therapeutics
name: Cyclacel Pharmaceuticals, Inc.
First posted: 2016-01-07
Enrollment: 49
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This is a phase II, dose ranging, multicenter, randomized, double-blind, placebo-controlled study.

The aim of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive days (treatment "on") separated by a 3 days treatment free period (treatment "off") in adult CF subjects with Cystic Fibrosis carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa.

This study involved 36 Cystic Fibrosis patients: 24 treated and 12 controls.

Detailed description: ROSCO-CF is a phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of (R)-roscovitine in subjects with Cystic Fibrosis carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa.

The aim of this study is to assess the safety of increasing doses of roscovitine administered orally for 4 cycles of 4 consecutive days (treatment "on") separated by a 3 days treatment free period (treatment "off") in 36 adult cystic fibrosis subjects.

These 36 patients will be allocated to 3 groups of 12 subjects who will be randomized in a 2:1 ratio (active drug to matching placebo). In each group, 8 patients will receive roscovitine (200 mg, 400 mg, 2 X 400 mg in group 1, 2 and 3, respectively) and 4 will receive a matching placebo. Treatment will be provided by oral administration of capsules. Each patient will receive the same treatment throughout the 28 day study.

This phase II trial will give some preliminary information about safety and hints of effects of a new experimental treatment. If the data suggest that a short term treatment with roscovitine provides a safe, effective and convenient approach for CF patients chronically infected with Pseudomonas aeruginosa, patients participating in this proof of concept trial will be offered to participate in further longer term studies.

Eligibility criteria: Inclusion Criteria:

* Male or female aged over 18 years of age on the date of informed consent;
* Diagnosed CF patients. Confirmed diagnosis of CF (Rosenstein and Cutting, 1998);
* Patients carrying 2 Cystic Fibrosis causing mutations with at least one F508del-CFTR mutation, genotype to be confirmed at screening;
* Forced expiratory volume at 1 second (FEV1) 40%
* Chronic lung Pseudomonas aeruginosa infection according to the definition from the French Consensus Conference;
* Able to understand and comply with all protocol requirements, restrictions and instructions and likely to complete the study as planned (as judged by the investigator);
* Provide written informed consent prior to the performance of any study-related procedure;

Exclusion Criteria:

* Acute upper or lower respiratory infection, pulmonary exacerbation or changes in therapy (including antibiotics) for pulmonary disease within 4 weeks before V2;
* Recent patient reported history of:

  * non recovered viral upper respiratory tract infection
  * solid organ or hematological transplantation
  * Burkholderia cepacia complex or Non Tuberculous Mycobacteria (NTM) respiratory tract infection;
* Undergone major surgery within 1 month prior to screening;
* Currently treated allergic broncho-pulmonary aspergillosis (ABPA);
* Diabetic patients whose blood glucose is poorly controlled as evidenced by HbA1C \>8%;
* Hemoptysis more than 60 mL at any time within 4 weeks prior to first study drug administration (V2);
* History of any other comorbidity that, in the opinion of the investigator, might confound the results of the study or pose an additional risk in administering study drug to the subject;
* Any other clinically significant conditions (not associated with the study indication) at Screening (V1) which might interfere with the assessment of this study;
* Any of the following abnormal laboratory values at screening:

  * Hemoglobin \<10 g/dL
  * Abnormal liver function
  * Serum K+ \<3,5 mmol/L
  * Abnormal renal function
* Any clinically significant laboratory abnormalities;
* Patients who have clinically significant impairment in cardiovascular function;
* Concomitant disease(s) that could prolong the QT interval;
* Patients with a history of alcohol or drug abuse in the past year;
* Patients with a history of noncompliance to medical regimens and patients or caregivers who are considered potentially unreliable;
* Use of one (or several) prohibited medications and/or food;
* Administration of any investigational drug within 30 days prior to Screening (V1) or 5 half-lives, whichever is longer;
* Use of systemic anti-pseudomonal antibiotics within 28 days prior to first study drug administration (V2). However use of inhaled anti-pseudomonal antibiotic treatment is allowed if initiated for more than 28 days;
* Use of loop diuretics within 7 days prior to first study drug administration (V2);
* Pregnant or nursing females.

Primary outcomes:
measure: Safety of increasing doses of Roscovitine
timeFrame: 3 months
Secondary outcomes:
measure: Change in the concentration of Pseudomonas Aeruginosa
timeFrame: 3 months
measure: PK parameters
timeFrame: 3 months
measure: Pro- and anti-inflammatory cytokines
timeFrame: 3 months
measure: C-reactive protein
timeFrame: 3 months
measure: Cystic Fibrosis Questionnaire-Revised
timeFrame: 3 months
measure: Body Mass Index
timeFrame: 3 months
measure: Forced expiratory volume in 1 second
timeFrame: 3 months
measure: Sweat Chloride Concentration
timeFrame: 3 months
measure: Nasal Potential Difference
timeFrame: 3 months
measure: Pain questionnaire
timeFrame: 3 months
Other outcomes:
Locations:
city: Lille
country: France
facility: CHR - Hôpital Calmette
city: Lyon
country: France
facility: CH Lyon Sud
city: Montpellier
country: France
facility: Hôpital Arnaud de Villeneuve
city: Nantes
country: France
facility: CHU Nantes
city: Nice
country: France
facility: CHU de Nice - Hôpital Pasteur
city: Paris
country: France
facility: Hôpital Cochin
city: Pessac
country: France
facility: CHU de Bordeaux - Hôpital Haut-Lévêque
city: Reims
country: France
facility: Centre de Ressources et de Compétences de la mucoviscidose
city: Roscoff
country: France
facility: Centre de Perharidy
city: Toulouse
country: France
facility: Hôpital Larrey
city: Vannes
country: France
facility: Centre Hospitalier Bretagne Atlantique
Study officials:
affiliation: Centre de Pérharidy - Roscoff
name: Gilles RAULT, MD
role: PRINCIPAL_INVESTIGATOR
References: